5Vote!
PR News Wire (Free subscription) | 11/02/2009
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira...
+Vote!
PR News Wire (Free subscription) | 15 hours ago
... This boost is due in part to physicians' increased prescribing of Centocor Ortho Biotech's Remicade as a second- or third-line therapy for newly diagnosed patients.
5Vote!
Brass and Ivory (Free subscription) | 12/01/2009
... had an inadequate response to one or more TNF antagonist therapies (such as Humira, Enbrel, or Remicade). Those of us living with multiple sclerosis CANNOT use one of the anti-TNF disease-modifying anti-rheumatic drugs (DMARDs) which are commonly used in the treatment of RA or other rheumatic diseases. This is because the anti-TNF drugs are known to increase disease activity in patients...
4Vote!
How The West Was Spun (Free subscription) | 11/18/2009
Project #1: Flutter Scarf I forgot I was going to have some in-hospital knit time this week, so I took this along for my Remicade therapy on Monday and got quite a bit accomplished. I finished up the pretty ruffled...
5Vote!
Dividend Growth Investor (Free subscription) | 11/18/2009
... years in a row. The ten-year average dividend growth for the producer of Neutrogena, Tylenol and Remicade is an impressive 13.30% annually. ( analysis ) Procter & Gamble (PG) has rewarded shareholders with dividend raises for 53 consecutive years. This consumer good juggernaut has managed to increase distributions at a rate of 10.70% annually over the past decade. ( analysis ) Pepsi...
3Vote!
The Daily Blague (Free subscription) | 11/18/2009
When I left the apartment for today’s Remicade infusion, I was very cross. I had spent too much time on the Daily Office, not only choosing links but writing them up, and by the time I regained track of the time and got dressed, it was too late for any kind of lunch. I was [...]
5Vote!
Fool.com (Free subscription) | 11/10/2009
... target the same molecule could become blockbusters: Abbott Labs' Humira, Johnson & JohnsonMerck Remicade, and PfizerAmgen Enbrel all target TNF-alpha and combined to bring in last year.
3Vote!
GuruFocus Updates (Free subscription) | 11/18/2009
... years in a row. The ten-year average dividend growth for the producer of Neutrogena, Tylenol and Remicade is an impressive 13.30% annually. ()Procter & Gamble () has rewarded shareholders with dividend raises for 53 consecutive years. This consumer good juggernaut has managed to increase distributions at a rate of 10.70% annually over the past decade. ()Pepsi Co () has increased its dividends...
5Vote!
Indy Star (Free subscription) | 11/04/2009
Biologic drugs, those made from living organisms instead of from chemicals, are increasingly used to treat arthritis, cancer, diabetes and other diseases. They're also more expensive for drug makers to produce and for patients to buy. The breast cancer drug Herceptin can cost $48,000 a year, and the rheumatoid arthritis drug Remicade can cost about $20,000.
+Vote!
Food and Drug Adminstration (FDA): Patient Safety News (Free subscription) | 11/01/2009
FDA is requiring stronger warnings about an increased risk of lymphoma and other cancers in children and adolescents who are treated with drugs that block tumor necrosis factor. TNF blockers include Remicade (infliximab), Enbrel (etancercept), Humir...
5Vote!
The Philadelphia Business Journal (Free subscription) | 11/03/2009
... unresolved following the merger is Merck’s rights to sales of Centocor’s arthritis medicine Remicade outside of the United States.Schering-Plough acquired those rights from Johnson & Johnson (NYSE:JNJ), which owns Centocor Ortho Biotech of Horsham, Pa. Johnson & Johnson is claiming the merger terminates the deal under a change-of-control provision in its agreement with Schering-Plough.Merck...
5Vote!
Forbes (Free subscription) | 10/29/2009
Swedish researchers analyzed data from 6,366 rheumatoid arthritis patients who started anti-TNF therapy with infliximab (Remicade), adalimumab (Humira) or etanercept (Enbrel) between January 1999 and July 2006. The study participants were compared with other groups of rheumatoid arthritis patients, including 61,160 not taking medications, 4,015 taking methotrexate (the gold standard of treatment)...
5Vote!
Science Daily (Free subscription) | 10/29/2009
TNF is a cytokine (substance secreted by immune system cells) that regulates the body's immune system and is involved in inflammation. TNF inhibitors (or TNF blockers) are a class of therapies used to reduce inflammation in chronic inflammation such as RA. The common immunosuppressant drugs and those included in the study are Remicade®, HumiraTM, and Enbrel®. As these therapies are used to treat...
